Concord Medical Stock Price, News & Analysis

Concord Medical Services Holdings Limited (NYSE: CCM) reported strong financial results for the first half of 2021, with total net revenues reaching RMB192.9 million ($29.9 million), a 132.4% increase from RMB83.0 million in the same period last year. The revenue split included RMB128.7 million from the network business and RMB64.2 million from hospitals. Gross profit improved to RMB2.4 million, recovering from a loss of RMB3.5 million in 2020. However, the net loss attributable to shareholders decreased to RMB90.3 million from RMB128.8 million. The company opened a new hospital and internet hospital, enhancing its service offerings.

Concord Medical Services Holdings Limited (NYSE: CCM) announced its 2021 annual general meeting of shareholders will take place on December 29, 2021, in Beijing. The meeting is for discussing company affairs with management, with no proposals for shareholder approval. The shareholder record date is November 29, 2021. The company's audited financial statements for the year ending December 31, 2020, are available on their investor relations website. Concord Medical specializes in cancer treatment and operates numerous advanced cancer hospitals and diagnostic centers across China.

Concord Medical Services Holdings Limited (NYSE: CCM) announced that its Guangzhou Concord Cancer Center (GCCC) has become a designated medical institution for Social Healthcare Insurance, enhancing patient access to healthcare. The National Healthcare Security Administration supports this system, covering over 95% of China's population. In Guangzhou, it can pay up to 90% of medical services. GCCC also partnered with various insurance companies, ensuring extensive coverage for patients. Operating since 2010, GCCC provides comprehensive cancer services from prevention to recovery, supported by Meizhong Jiahe Medical Science & Technology Development Group.

Concord Medical Services Holdings Limited (NYSE: CCM) announced two projects shortlisted for the '5G+Healthcare' pilot project by China's Ministry of Industry and Information Technology. The projects include the Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform, which offers solutions for remote diagnosis, and the Jiahe Feiyun Intelligent Radiotherapy Cloud Service Platform, providing comprehensive radiotherapy management services. This recognition highlights Concord's commitment to advancing cancer care in China through technology.

Concord Medical Services Holdings Limited (NYSE: CCM) filed its annual report on Form 20-F for the fiscal year ending December 31, 2020. The report is accessible on the Company's investor relations and SEC websites. Concord Medical specializes in cancer treatment and operates an extensive network of cancer hospitals and diagnostic centers across China. Additionally, the Company has established proton therapy facilities and focuses on advanced cancer care and medical equipment services. Shareholders can request a hard copy of the report free of charge.

Concord Medical Services Holdings Limited (NYSE: CCM) announced that its subsidiary, Shanghai Concord Cancer Center, has entered an agreement to purchase the Proteus Plus proton therapy system from CGN Medical Technology. Located in Shanghai, the center is under construction since September 2017 and aims to be a leading facility for cancer treatment, covering 70 acres with over 400 beds. The hospital will offer a multidisciplinary approach to cancer care and leverage advanced international technologies.

Concord Medical Services Holdings Limited (NYSE: CCM) announced an investment of RMB400 million (approximately US$62.2 million) in its subsidiary, Meizhong Jiahe Medical Science & Technology Development Group. The investment, led by WisdoMont Capital, aims to enhance the development and management of cancer hospitals and diagnostic centers in China. Meizhong Jiahe focuses on high-quality cancer care, including advanced proton therapy treatments in cities like Beijing, Shanghai, and Guangzhou. This funding solidifies Concord Medical's leadership in China's expanding cancer treatment market.

Concord Medical Services Holdings Limited (CCM) announced the opening of its Guangzhou Concord Cancer Center (GCCC), certified as a tertiary specialty hospital by the National Health Commission. Located in Sino-Singapore Guangzhou Knowledge City, GCCC meets the highest domestic medical standards and features advanced technologies like the Probeam proton system for precise cancer treatment. Operated by a subsidiary, GCCC aims to offer comprehensive cancer care, including prevention, diagnosis, and recovery services. This milestone enhances Concord Medical's capabilities within the growing cancer treatment market in China.

Concord Medical Services Holdings Limited (NYSE: CCM) announced a delay in filing its 2020 Annual Report with the SEC, originally due by May 17, 2021. The late filing was communicated via Form 12b-25 on April 30, 2021. The NYSE notified Concord Medical that it is not compliant with its listing requirements due to this delay, and the company is under review for up to six months. If the report is not filed within this timeframe, delisting could occur. As of now, the anticipated filing date remains unknown.